Drugs / Universal donor derived CD33 CAR-NK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07026942 | Apr 2026 → Jul 2032 expected | acute myeloid leukemia | Nationwide Children's Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Universal donor derived CD33 CAR-NK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07026942 ↗ |
| Known as | CD33 CAR-NK cells | “The treatment uses specially modified immune cells (called CD33 CAR-NK cells) from a healthy, unrelated donor to attack the cancer.” NCT07026942 ↗ |
| Known as | CD38KO CD33 CAR-NK | “Universal donor derived CD38KO CD33 CAR-NK manuctured on-site.” NCT07026942 ↗ |
| Modality | Cell therapy | “The treatment uses specially modified immune cells (called CD33 CAR-NK cells) from a healthy, unrelated donor to attack the cancer.” NCT07026942 ↗ |
| Target | CD33 | “using AAV6 vector to insert a CD33-targeted CAR gene into the CD38 locus” NCT07026942 ↗ |